Abstract:For decades, the success of allogeneic hematopoietic stem cell transplant has highlighted the role of T cells in eliminating hematological tumors. This proof of concept pioneered the practice of the ex vivo generation and adoptive transfer of tumor-specific T cells (ATC), which became an effective modality, for example, for virus-associated diseases, like Epstein-Barr-virus-associated post-transplant lymphoproliferative disorders ( 1 ). A remarkable advance to the ATC field was pioneered by Eshhar and colleagues in 1993, when, rather than replicating the T-cell receptor (TCR)-mediated recognition of tumor molecules, which requires antigen processing and presentation through major histocompatibility complex (MHC) molecules, they generated chimeric antigen receptors (CAR) that target unprocessed antigens expressed on the cell surface of tumor cells in an MHC unrestricted fashion ( 2 ). Providing T cells with the ability to engage targets via an antibody-derived single-chain-variable-fragment (scFv) linked to the intracellular T-cell signaling domains was game changing because it overcomes HLA barriers and opens a whole new antigen repertoire for tumor recognition. While the first clinical application of CAR-T cells was for treatment of patients with HIV ( 3 ), this approach gained the most traction in hematological malignancies and was driven by the availability of lineage restricted antigens homogeneously expressed by hematological tumors. Specifically, targeting B-cell malignancies offered a much-needed route to success ( 4 – 6 ). The CD19 antigen promptly took the spotlight as meeting the fundamental requirements for ideal CAR targeting, namely: its high expression on tumor cells, expression at all stages of B-cell development and thus on derived tumors, and absent expression on vital tissues, with the potential for B-cell aplasia considered a risk-benefit ratio worth taking ( 7 ). The other major advantage provided by hematological malignancies is their accessibility. CAR-T cells infused intravenously are much more likely to interact with tumor cells that are circulating in the blood or located in the bone marrow and lymph nodes (or lymphatic system), compared with the those that require penetrating through a solid tumor stroma. Moving this technology to cancer treatment also required several advances in the laboratory. First, genetic modification of human cells became more mainstream, thanks to the development of efficient viral vectors, like lenti- and retro-virus based vectors, combined with the development of better protocols for vector production, cell transduction, and newer technologies for their safety monitoring ( 3 , 8 ). Second, recognizing the need for a costimulatory signal (known as signal 2) to promote full T-cell activation was key. The provision of just the CD3ζ or CD3γ endodomains that trigger the proximal signaling of the TCR to the first-generation CAR was in fact unable to replicate the physiological sequence of activation events that occur upon TCR engagement and proved to be sub-optimal in supporting CAR-T cell expansion and persistence ( 9 ). In contrast, including the intracellular domains of molecules such as CD28 or 4-1BB in tandem with the CAR supported the transmission of signals capable of producing the required sustained activation, proliferation, and effector function ( 10 – 12 ).

Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T cells for treating autoimmune diseases

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR T Cells: A Snapshot on the Growing Options to Design a CAR

Chimeric Antigen Receptor-T (CAR-T) Cells as “Living Drugs”: A Clinical Pharmacist Perspective

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

CAR T therapy beyond cancer: the evolution of a living drug

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Driving CAR T-cells forward

CAR T cells for hematological malignancies

CAR T cells: Building on the CD19 paradigm

CAR T-cell immunotherapy of B-cell malignancy: the story so far

CAR T‐cell therapy: Full speed ahead

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

From bench to bedside: the history and progress of CAR T cell therapy

CAR-T cells, from principle to clinical applications